Research · PMID 41447991
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Practice guideline for the treatment and management of iatrogenic premature ovarian insufficiency.
Maturitas · February 2026 · Xiangyan Ruan, Che Xu, Hefeng Huang, Binghe Xu, Chenghong Yin, et al.
What this study found
It is well known that premature ovarian insufficiency (POI) seriously affects the fertility, quality of life, and health of young women. A meta-analysis of global data indicated that the current population prevalence of POI is as high as 3.7 %, but exceeds 10 % in some countries and regions.
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Primary study
Should women with early surgical menopause receive hormone therapy?
Women with premature or early surgical menopause should generally receive hormone therapy until the average age of natural menopause unless contraindicated, to mitigate bone, cardiovascular, and symptom burden associated with early estrogen loss.
Open evidence analysisSupporting literature
Does hormone replacement therapy increase breast cancer risk?
Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.
Open evidence analysis